The human disease tuberculosis (TB) is the leading cause of death from a single infectious agent. A quarter of the world’s population is estimated to be latently infected. Drug development and screening is slow and costly. We have developed a physiologically relevant assay to screen drugs against TB when inside immune cells. This chapter will describe a newly developed preclinical drug screening assay for TB, using high-content imaging and pharmacokinetic/pharmacodynamic modeling.
Donnellan, S., Martínez-Rodríguez, C., Aljayyoussi, G., & Biagini, G. A. (2021). Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi). In C. Barreiro, & J. Barredo (Eds.), Antimicrobial Therapies: Methods and Protocols (393-408). New York: Humana Press. https://doi.org/10.1007/978-1-0716-1358-0